Emerging metabolic targets in cancer therapy

Frontiers in Bioscience

Volumn 16, Issue 5, 2011, Pages 1844-1860

  Zhao, Yuhua ^a   Liu, Hao ^a   Riker, Adam I ^b   Fodstad, Oystein ^c   Ledoux, Susan P ^d   Wilson, Glenn L ^d   Tan, Ming ^a,d  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b Ochsner Cancer Institute   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer therapy; Glycolysis; Metabolism; Oncogene; Review; Warburg effect

Indexed keywords

ADENYLATE KINASE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; PYRUVATE KINASE; TARGET OF RAPAMYCIN KINASE;

CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; METABOLISM; NEOPLASM; ONCOGENE MYC; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ADENYLATE KINASE; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; ENZYME INHIBITORS; GENES, MYC; GLYCOLYSIS; HEXOKINASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVATE KINASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79955023800     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3826     Document Type: Article

References (126)

1. Z. Chen, W. Lu, C. Garcia-Prieto and P. Huang: The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr, 39, 267-274 (2007) (Pubitemid 47619379)
2. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou and C. B. Thompson: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 7, 11-20 (2008)
3. R. A. Gatenby and R. J. Gillies: Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol, 39, 1358-1366 (2007) (Pubitemid 47031043)
4. R. J. Gillies, I. Robey and R. A. Gatenby: Causes and consequences of increased glucose metabolism of cancers. J Nucl Med, 49 Suppl 2, 24S-42S (2008) (Pubitemid 351948035)
5. P. P. Hsu and D. M. Sabatini: Cancer cell metabolism: Warburg and beyond. Cell, 134, 703-707 (2008)
6. J. W. Kim and C. V. Dang: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res, 66, 8927-8930 (2006) (Pubitemid 44521105)
7. G. Kroemer and J. Pouyssegur: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 13, 472-482 (2008) (Pubitemid 351766797)
8. O. Warburg: On the origin of cancer cells. Science, 123, 309-314 (1956)
9. D. A. Tennant, R. V. Duran and E. Gottlieb: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer, 10, 267-277
10. R. A. Gatenby and R. J. Gillies: Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 4, 891-899 (2004) (Pubitemid 39472955)
11. M. G. Vander Heiden, L. C. Cantley and C. B. Thompson: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-1033 (2009)
12. T. W. Secomb, R. Hsu, R. D. Braun, J. R. Ross, J. F. Gross and M. W. Dewhirst: Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol, 454, 629-634 (1998)
13. P. Vaupel: Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol, 14, 198-206 (2004) (Pubitemid 38903223)
14. Y. Chen, R. Cairns, I. Papandreou, A. Koong and N. C. Denko: Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One, 4, e7033 (2009)
15. A. L. Harris: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer, 2, 38-47 (2002) (Pubitemid 37328806)
16. G. L. Wang, B. H. Jiang, E. A. Rue and G. L. Semenza: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 92, 5510-5514 (1995)
17. S. Salceda and J. Caro: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem, 272, 22642-22647 (1997) (Pubitemid 27386079)
18. J. D. Gordan, C. B. Thompson and M. C. Simon: HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell, 12, 108-113 (2007) (Pubitemid 47199124)
19. J. W. Kim, I. Tchernyshyov, G. L. Semenza and C. V. Dang: HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 3, 177-185 (2006)
20. C. W. Lu, S. C. Lin, K. F. Chen, Y. Y. Lai and S. J. Tsai: Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem, 283, 28106-28114 (2008)
21. I. Papandreou, R. A. Cairns, L. Fontana, A. L. Lim and N. C. Denko: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab, 3, 187-197 (2006)
22. V. R. Fantin, J. St-Pierre and P. Leder: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 9, 425-434 (2006) (Pubitemid 43832190)
23. A. J. Folkes, K. Ahmadi, W. K. Alderton, S. Alix, S. J. Baker, G. Box, I. S. Chuckowree, P. A. Clarke, P. Depledge, S. A. Eccles, L. S. Friedman, A. Hayes, T. C. Hancox, A. Kugendradas, L. Lensun, P. Moore, A. G. Olivero, J. Pang, S. Patel, G. H. Pergl-Wilson, F. I. Raynaud, A. Robson, N. Saghir, L. Salphati, S. Sohal, M. H. Ultsch, M. Valenti, H. J. Wallweber, N. C. Wan, C. Wiesmann, P. Workman, A. Zhyvoloup, M. J. Zvelebil and S. J. Shuttleworth: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem, 51, 5522-5532 (2008)
24. R. J. Shaw: Glucose metabolism and cancer. Curr Opin Cell Biol, 18, 598-608 (2006) (Pubitemid 44692479)
25. M. G. Vander Heiden, H. R. Christofk, E. Schuman, A. O. Subtelny, H. Sharfi, E. E. Harlow, J. Xian and L. C. Cantley: Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol, 79, 1118-1124
26. R. L. Elstrom, D. E. Bauer, M. Buzzai, R. Karnauskas, M. H. Harris, D. R. Plas, H. Zhuang, R. M. Cinalli, A. Alavi, C. M. Rudin and C. B. Thompson: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res, 64, 3892-3899 (2004) (Pubitemid 38697301)
27. R. B. Robey and N. Hay: Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol, 19, 25-31 (2009)
28. K. L. Talks, H. Turley, K. C. Gatter, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe and A. L. Harris: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 157, 411-421 (2000) (Pubitemid 30626905)
29. H. Zhong, A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza and J. W. Simons: Overexpression of hypoxiainducible factor 1alpha in common human cancers and their metastases. Cancer Res, 59, 5830-5835 (1999)
30. G. L. Semenza: Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3, 721-732 (2003) (Pubitemid 37328811)
31. M. Eilers and R. N. Eisenman: Myc's broad reach. Genes Dev, 22, 2755-2766 (2008)
32. C. V. Dang, A. Le and P. Gao: MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res, 15, 6479-6483 (2009)
33. H. Shim, C. Dolde, B. C. Lewis, C. S. Wu, G. Dang, R. A. Jungmann, R. Dalla-Favera and C. V. Dang: c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A, 94, 6658-6663 (1997) (Pubitemid 27281920)
34. J. W. Kim, K. I. Zeller, Y. Wang, A. G. Jegga, B. J. Aronow, K. A. O'Donnell and C. V. Dang: Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol, 24, 5923-5936 (2004) (Pubitemid 38787976)
35. R. C. Osthus, H. Shim, S. Kim, Q. Li, R. Reddy, M. Mukherjee, Y. Xu, D. Wonsey, L. A. Lee and C. V. Dang: Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem, 275, 21797-21800 (2000) (Pubitemid 30621745)
36. D. R. Wise, R. J. DeBerardinis, A. Mancuso, N. Sayed, X. Y. Zhang, H. K. Pfeiffer, I. Nissim, E. Daikhin, M. Yudkoff, S. B. McMahon and C. B. Thompson: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A, 105, 18782-18787 (2008)
37. P. Gao, I. Tchernyshyov, T. C. Chang, Y. S. Lee, K. Kita, T. Ochi, K. I. Zeller, A. M. De Marzo, J. E. Van Eyk, J. T. Mendell and C. V. Dang: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 458, 762-765 (2009)
38. M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam and Y. Lazebnik: Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol, 178, 93-105 (2007) (Pubitemid 47026405)
39. F. Li, Y. Wang, K. I. Zeller, J. J. Potter, D. R. Wonsey, K. A. O'Donnell, J. W. Kim, J. T. Yustein, L. A. Lee and C. V. Dang: Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol, 25, 6225-6234 (2005) (Pubitemid 40946570)
40. J. E. Wilson: Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol, 206, 2049-2057 (2003) (Pubitemid 36761808)
41. S. P. Mathupala, Y. H. Ko and P. L. Pedersen: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene, 25, 4777-4786 (2006) (Pubitemid 44187625)
42. S. P. Mathupala, A. Rempel and P. L. Pedersen: Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem, 270, 16918-16925 (1995)
43. M. Tian, H. Zhang, T. Higuchi, N. Oriuchi, Y. Nakasone, K. Takata, N. Nakajima, K. Mogi and K. Endo: Hexokinase-II expression in untreated oral squamous cell carcinoma: comparison with FDG PET imaging. Ann Nucl Med, 19, 335-338 (2005) (Pubitemid 41105137)
44. R. B. Robey and N. Hay: Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene, 25, 4683-4696 (2006) (Pubitemid 44187618)
45. H. R. Christofk, M. G. Vander Heiden, N. Wu, J. M. Asara and L. C. Cantley: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 452, 181-186 (2008) (Pubitemid 351380242)
46. T. Hitosugi, S. Kang, M. G. Vander Heiden, T. W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G. Z. Chen, J. Xie, T. L. Gu, R. D. Polakiewicz, J. L. Roesel, T. J. Boggon, F. R. Khuri, D. G. Gilliland, L. C. Cantley, J. Kaufman and J. Chen: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal, 2, ra73 (2009)
47. H. R. Christofk, M. G. Vander Heiden, M. H. Harris, A. Ramanathan, R. E. Gerszten, R. Wei, M. D. Fleming, S. L. Schreiber and L. C. Cantley: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 452, 230-233 (2008) (Pubitemid 351380249)
48. M. Zhou, Y. Zhao, Y. Ding, H. Liu, Z. Liu, O. Fodstad, A. I. Riker, S. Kamarajugadda, J. Lu, L. B. Owen, S. P. Ledoux and M. Tan: Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxolresistant cancer cells to taxol. Mol Cancer, 9, 33
49. H. Xie, V. A. Valera, M. J. Merino, A. M. Amato, S. Signoretti, W. M. Linehan, V. P. Sukhatme and P. Seth: LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther, 8, 626-635 (2009)
50. A. Le, C. R. Cooper, A. M. Gouw, R. Dinavahi, A. Maitra, L. M. Deck, R. E. Royer, D. L. Vander Jagt, G. L. Semenza and C. V. Dang: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A, 107, 2037-2042 (2010)
51. D. Pathania, M. Millard and N. Neamati: Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev, 61, 1250-1275 (2009)
52. B. Pasini and C. A. Stratakis: SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med, 266, 19-42 (2009)
53. V. Yankovskaya, R. Horsefield, S. Tornroth, C. Luna-Chavez, H. Miyoshi, C. Leger, B. Byrne, G. Cecchini and S. Iwata: Architecture of succinate dehydrogenase and reactive oxygen species generation. Science, 299, 700-704 (2003) (Pubitemid 36159483)
54. M. A. Selak, S. M. Armour, E. D. MacKenzie, H. Boulahbel, D. G. Watson, K. D. Mansfield, Y. Pan, M. C. Simon, C. B. Thompson and E. Gottlieb: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIFalpha prolyl hydroxylase. Cancer Cell, 7, 77-85 (2005) (Pubitemid 40126384)
55. W. Habano, T. Sugai, S. Nakamura, N. Uesugi, T. Higuchi, M. Terashima and S. Horiuchi: Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncol Rep, 10, 1375-1380 (2003)
56. I. P. Tomlinson, N. A. Alam, A. J. Rowan, E. Barclay, E. E. Jaeger, D. Kelsell, I. Leigh, P. Gorman, H. Lamlum, S. Rahman, R. R. Roylance, S. Olpin, S. Bevan, K. Barker, N. Hearle, R. S. Houlston, M. Kiuru, R. Lehtonen, A. Karhu, S. Vilkki, P. Laiho, C. Eklund, O. Vierimaa, K. Aittomaki, M. Hietala, P. Sistonen, A. Paetau, R. Salovaara, R. Herva, V. Launonen and L. A. Aaltonen: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet, 30, 406-410 (2002)
57. S. Sudarshan, C. Sourbier, H. S. Kong, K. Block, V. A. Valera Romero, Y. Yang, C. Galindo, M. Mollapour, B. Scroggins, N. Goode, M. J. Lee, C. W. Gourlay, J. Trepel, W. M. Linehan and L. Neckers: Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol, 29, 4080-4090 (2009)
58. J. S. Isaacs, Y. J. Jung, D. R. Mole, S. Lee, C. Torres-Cabala, Y. L. Chung, M. Merino, J. Trepel, B. Zbar, J. Toro, P. J. Ratcliffe, W. M. Linehan and L. Neckers: HIF overexpression correlates with biallelic loss of fumaratehydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell, 8, 143-153 (2005) (Pubitemid 41132743)
59. D. W. Parsons, S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I. M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz, Jr., J. Hartigan, D. R. Smith, R. L. Strausberg, S. K. Marie, S. M. Shinjo, H. Yan, G. J. Riggins, D. D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu and K. W. Kinzler: An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-1812 (2008)
60. G. T. Jennings, K. I. Minard and L. McAlister-Henn: Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase. Biochemistry, 36, 13743-13747 (1997) (Pubitemid 27481624)
61. H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein and D. D. Bigner: IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360, 765-773 (2009)
62. C. B. Thompson: Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med, 360, 813-815 (2009)
63. I. S. Kil, T. L. Huh, Y. S. Lee, Y. M. Lee and J. W. Park: Regulation of replicative senescence by NADP+ -dependent isocitrate dehydrogenase. Free Radic Biol Med, 40, 110-119 (2006) (Pubitemid 41759408)
64. F. Schwartzenberg-Bar-Yoseph, M. Armoni and E. Karnieli: The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res, 64, 2627-2633 (2004) (Pubitemid 38523921)
65. K. Kawauchi, K. Araki, K. Tobiume and N. Tanaka: p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol, 10, 611-618 (2008) (Pubitemid 351627381)
66. N. Durany, J. Joseph, E. Campo, R. Molina and J. Carreras: Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer, 75, 969-977 (1997) (Pubitemid 27122614)
67. N. Durany, J. Joseph, O. M. Jimenez, F. Climent, P. L. Fernandez, F. Rivera and J. Carreras: Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br J Cancer, 82, 20-27 (2000) (Pubitemid 30008953)
68. H. Kondoh, M. E. Lleonart, J. Gil, J. Wang, P. Degan, G. Peters, D. Martinez, A. Carnero and D. Beach: Glycolytic enzymes can modulate cellular life span. Cancer Res, 65, 177-185 (2005) (Pubitemid 40070808)
69. K. Bensaad, A. Tsuruta, M. A. Selak, M. N. Vidal, K. Nakano, R. Bartrons, E. Gottlieb and K. H. Vousden: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126, 107-120 (2006) (Pubitemid 44040989)
70. S. D. Westerheide and R. I. Morimoto: Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem, 280, 33097-33100 (2005) (Pubitemid 41397104)
71. C. Dai, L. Whitesell, A. B. Rogers and S. Lindquist: Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell, 130, 1005-1018 (2007) (Pubitemid 47410269)
72. M. A. Khaleque, A. Bharti, J. Gong, P. J. Gray, V. Sachdev, D. R. Ciocca, A. Stati, M. Fanelli and S. K. Calderwood: Heat shock factor 1 represses estrogendependent transcription through association with MTA1. Oncogene, 27, 1886-1893 (2008) (Pubitemid 351430827)
73. M. A. Khaleque, A. Bharti, D. Sawyer, J. Gong, I. J. Benjamin, M. A. Stevenson and S. K. Calderwood: Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene, 24, 6564-6573 (2005) (Pubitemid 41486639)
74. J. N. Min, L. Huang, D. B. Zimonjic, D. Moskophidis and N. F. Mivechi: Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene, 26, 5086-5097 (2007) (Pubitemid 47206948)
75. Y. H. Zhao, M. Zhou, H. Liu, Y. Ding, H. T. Khong, D. Yu, O. Fodstad and M. Tan: Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene, 28, 3689-3701 (2009)
76. J. C. Maher, A. Krishan and T. J. Lampidis: Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-Dglucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol, 53, 116-122 (2004) (Pubitemid 38186989)
77. R. M. Lynch, K. E. Fogarty and F. S. Fay: Modulation of hexokinase association with mitochondria analyzed with quantitative three-dimensional confocal microscopy. J Cell Biol, 112, 385-395 (1991) (Pubitemid 21925994)
78. H. Liu, Y. P. Hu, N. Savaraj, W. Priebe and T. J. Lampidis: Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry, 40, 5542-5547 (2001) (Pubitemid 32458256)
79. H. Liu, N. Savaraj, W. Priebe and T. J. Lampidis: Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol, 64, 1745-1751 (2002) (Pubitemid 35351581)
80. G. Maschek, N. Savaraj, W. Priebe, P. Braunschweiger, K. Hamilton, G. F. Tidmarsh, L. R. De Young and T. J. Lampidis: 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res, 64, 31-34 (2004) (Pubitemid 38114078)
81. D. Singh, A. K. Banerji, B. S. Dwarakanath, R. P. Tripathi, J. P. Gupta, T. L. Mathew, T. Ravindranath and V. Jain: Optimizing cancer radiotherapy with 2-deoxy-dglucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol, 181, 507-514 (2005) (Pubitemid 41059520)
82. D. Zhong, X. Liu, K. Schafer-Hales, A. I. Marcus, F. R. Khuri, S. Y. Sun and W. Zhou: 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther, 7, 809-817 (2008) (Pubitemid 351551034)
83. D. Zhong, L. Xiong, T. Liu, X. Liu, X. Liu, J. Chen, S. Y. Sun, F. R. Khuri, Y. Zong, Q. Zhou and W. Zhou: The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem, 284, 23225-23233 (2009)
84. R. Scatena, P. Bottoni, A. Pontoglio, L. Mastrototaro and B. Giardina: Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs, 17, 1533-1545 (2008)
85. A. Floridi, M. G. Paggi, M. L. Marcante, B. Silvestrini, A. Caputo and C. De Martino: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst, 66, 497-499 (1981) (Pubitemid 11098551)
86. A. Floridi, T. Bruno, S. Miccadei, M. Fanciulli, A. Federico and M. G. Paggi: Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol, 56, 841-849 (1998) (Pubitemid 28458978)
87. M. De Lena, V. Lorusso, A. Latorre, G. Fanizza, G. Gargano, L. Caporusso, M. Guida, A. Catino, E. Crucitta, D. Sambiasi and A. Mazzei: Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer, 37, 364-368 (2001) (Pubitemid 32182325)
88. S. Di Cosimo, G. Ferretti, P. Papaldo, P. Carlini, A. Fabi and F. Cognetti: Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc), 39, 157-174 (2003)
89. S. Oudard, A. Carpentier, E. Banu, F. Fauchon, D. Celerier, M. F. Poupon, B. Dutrillaux, J. M. Andrieu and J. Y. Delattre: Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol, 63, 81-86 (2003) (Pubitemid 36681647)
90. P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, S. Di Cosimo, C. Nistico, P. Carlini, F. Conti, L. Di Lauro, C. Botti, C. Vitucci, A. Fabi, D. Giannarelli and P. Marolla: Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol, 21, 3462-3468 (2003) (Pubitemid 46603516)
91. J. F. Geschwind, C. S. Georgiades, Y. H. Ko and P. L. Pedersen: Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther, 4, 449-457 (2004) (Pubitemid 38745116)
92. Y. H. Ko, P. L. Pedersen and J. F. Geschwind: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett, 173, 83-91 (2001) (Pubitemid 32907513)
93. R. H. Xu, H. Pelicano, Y. Zhou, J. S. Carew, L. Feng, K. N. Bhalla, M. J. Keating and P. Huang: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res, 65, 613-621 (2005)
94. J. F. Geschwind, Y. H. Ko, M. S. Torbenson, C. Magee and P. L. Pedersen: Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res, 62, 3909-3913 (2002) (Pubitemid 34791050)
95. Y. H. Ko, B. L. Smith, Y. Wang, M. G. Pomper, D. A. Rini, M. S. Torbenson, J. Hullihen and P. L. Pedersen: Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun, 324, 269-275 (2004) (Pubitemid 39311489)
96. R. H. Xu, H. Pelicano, H. Zhang, F. J. Giles, M. J. Keating and P. Huang: Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia, 19, 2153-2158 (2005) (Pubitemid 41741609)
97. X. Cao, M. Bloomston, T. Zhang, W. L. Frankel, G. Jia, B. Wang, N. C. Hall, R. M. Koch, H. Cheng, M. V. Knopp and D. Sun: Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res, 14, 1831-1839 (2008) (Pubitemid 351469470)
98. G. A. Spoden, S. Mazurek, D. Morandell, N. Bacher, M. J. Ausserlechner, P. Jansen-Durr, E. Eigenbrodt and W. Zwerschke: Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer, 123, 312-321 (2008) (Pubitemid 351842015)
99. G. A. Spoden, U. Rostek, S. Lechner, M. Mitterberger, S. Mazurek and W. Zwerschke: Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res, 315, 2765-2774 (2009)
100. S. Mazurek: Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol
101. H. F. Duan, X. W. Hu, J. L. Chen, L. H. Gao, Y. Y. Xi, Y. Lu, J. F. Li, S. R. Zhao, J. J. Xu, H. P. Chen, W. Chen and C. T. Wu: Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. J Natl Cancer Inst, 99, 1551-1555 (2007) (Pubitemid 351767233)
102. W. Guo, Y. Zhang, T. Chen, Y. Wang, J. Xue, Y. Zhang, W. Xiao, X. Mo and Y. Lu: Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol
103. T. McFate, A. Mohyeldin, H. Lu, J. Thakar, J. Henriques, N. D. Halim, H. Wu, M. J. Schell, T. M. Tsang, O. Teahan, S. Zhou, J. A. Califano, N. H. Jeoung, R. A. Harris and A. Verma: Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem, 283, 22700-22708 (2008)
104. K. Garber: Energy deregulation: licensing tumors to grow. Science, 312, 1158-1159 (2006)
105. T. E. Roche and Y. Hiromasa: Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol Life Sci, 64, 830-849 (2007) (Pubitemid 46597752)
106. S. Bonnet, S. L. Archer, J. Allalunis-Turner, A. Haromy, C. Beaulieu, R. Thompson, C. T. Lee, G. D. Lopaschuk, L. Puttagunta, S. Bonnet, G. Harry, K. Hashimoto, C. J. Porter, M. A. Andrade, B. Thebaud and E. D. Michelakis: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 11, 37-51 (2007) (Pubitemid 46054520)
107. M. Kato, J. Li, J. L. Chuang and D. T. Chuang: Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure, 15, 992-1004 (2007) (Pubitemid 47212754)
108. E. D. Michelakis, L. Webster and J. R. Mackey: Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer, 99, 989-994 (2008)
109. R. C. Sun, M. Fadia, J. E. Dahlstrom, C. R. Parish, P. G. Board and A. C. Blackburn: Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat, 120, 253-260
110. C. J. Hu, L. Y. Wang, L. A. Chodosh, B. Keith and M. C. Simon: Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol, 23, 9361-9374 (2003) (Pubitemid 37499822)
111. M. Y. Koh, T. Spivak-Kroizman, S. Venturini, S. Welsh, R. R. Williams, D. L. Kirkpatrick and G. Powis: Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther, 7, 90-100 (2008)
112. S. Welsh, R. Williams, L. Kirkpatrick, G. Paine-Murrieta and G. Powis: Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther, 3, 233-244 (2004) (Pubitemid 39193698)
113. K. Lee, H. Zhang, D. Z. Qian, S. Rey, J. O. Liu and G. L. Semenza: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A, 106, 17910-17915 (2009)
114. T. T. Junttila, R. W. Akita, K. Parsons, C. Fields, G. D. Lewis Phillips, L. S. Friedman, D. Sampath and M. X. Sliwkowski: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell, 15, 429-440 (2009)
115. E. Yao, W. Zhou, S. T. Lee-Hoeflich, T. Truong, P. M. Haverty, J. Eastham-Anderson, N. Lewin-Koh, B. Gunter, M. Belvin, L. J. Murray, L. S. Friedman, M. X. Sliwkowski and K. P. Hoeflich: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res, 15, 4147-4156 (2009)
116. J. LoPiccolo, G. M. Blumenthal, W. B. Bernstein and P. A. Dennis: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat, 11, 32-50 (2008)
117. T. E. Witzig, S. M. Geyer, I. Ghobrial, D. J. Inwards, R. Fonseca, P. Kurtin, S. M. Ansell, R. Luyun, P. J. Flynn, R. F. Morton, S. R. Dakhil, H. Gross and S. H. Kaufmann: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol, 23, 5347-5356 (2005) (Pubitemid 46206988)
118. S. Chan, M. E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, M. Borner, M. Salzberg, V. Ostapenko, H. J. Illiger, D. Behringer, N. Bardy-Bouxin, J. Boni, S. Kong, M. Cincotta and L. Moore: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol, 23, 5314-5322 (2005) (Pubitemid 46206985)
119. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I. G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore and R. J. Motzer: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 356, 2271-2281 (2007) (Pubitemid 46849157)
120. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers and C. Garcia-Echeverria: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 7, 1851-1863 (2008)
121. V. Serra, B. Markman, M. Scaltriti, P. J. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, M. Maira, C. Garcia-Echeverria, J. L. Parra, J. Arribas and J. Baselga: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res, 68, 8022-8030 (2008)
122. C. R. Schnell, F. Stauffer, P. R. Allegrini, T. O'Reilly, P. M. McSheehy, C. Dartois, M. Stumm, R. Cozens, A. Littlewood-Evans, C. Garcia-Echeverria and S. M. Maira: Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVPBEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res, 68, 6598-6607 (2008)
123. J. A. Engelman, L. Chen, X. Tan, K. Crosby, A. R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S. A. Perera, Y. Song, L. R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R. F. Padera, C. Garcia-Echeverria, R. Weissleder, U. Mahmood, L. C. Cantley and K. K. Wong: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med, 14, 1351-1356 (2008)
124. I. Ben Sahra, Y. Le Marchand-Brustel, J. F. Tanti and F. Bost: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther, 9, 1092-1099
125. H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis and K. Struhl: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-7511 (2009)
126. H. Pelicano, D. S. Martin, R. H. Xu and P. Huang: Glycolysis inhibition for anticancer treatment. Oncogene, 25, 4633-4646 (2006) (Pubitemid 44187614)